Cancer Res 2011, 71:3991–4001.PubMedCrossRef 32. Dyall S, Gayther SA, Dafou D: Cancer stem cells and epithelial ovarian cancer. Oncology: Journal of; 2010:105269. 33. Bast RC Jr, Mills GB: Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 2010,28(22):3545–3548.PubMedCrossRef 34. Pardal R, Clarke
MF, Morrison SJ: Applying the principles of stem-cell biology to cancer. Nat Rev Cancer VX-765 ic50 2003, 3:895–902.PubMedCrossRef 35. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM: Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006, 66:9339–9344.PubMedCrossRef 36. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih IM: Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008, 198:351–356.PubMedCrossRef 37. Pisano
C, Bruni GS, Facchini G, Marchetti C, Pignata S: Treatment of recurrent epithelial ovarian cancer. Ther Clin Risk Manag 2009, 5:421–426.PubMed LY2157299 ic50 38. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A: Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010, 28:3323–3329.PubMedCrossRef 39. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM: Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010, 28:3107–3114.PubMedCrossRef
40. Benedetti-Panici P, Perniola G, Marchetti C, Pernice M, Donfrancesco C, Di Donato V, Tomao F, Palaia I, Graziano M, Basile S, Bellati F: Intraperitoneal chemotherapy click here by ultrasound-guided direct puncture in recurrent ovarian cancer: feasibility, compliance, and complications. Int J Gynecol Cancer 2012,22(6):1069–74.PubMedCrossRef 41. Tomao F, Panici PB, Frati L, Tomao S: Emerging role of pemetrexed in ovarian cancer. Expert Rev Anticancer Ther 2009,9(12):1727–35.PubMedCrossRef 42. Bellati F, Napoletano C, Gasparri ML, Ruscito I, Marchetti C, Pignata S, Tomao F, Benedetti Panici P, Nuti M: Current knowledge and open issues regarding bevacizumab in gynecological neoplasms. Crit Rev Oncol Hematol 2012,83(1):35–46.PubMedCrossRef 43. Tomao F, Benedetti Panici P, Tomao S: Improvement in progression free survival in oceans bevacizumab arm: a critical point of view. J Clin Oncol 2013,31(1):166–7.PubMedCrossRef 44. Guarneri V, Piacentini F, Barbieri E, Conte PF: Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol 2010,117(2):152–158.PubMedCrossRef 45.